Enanta Pharma Q2 2024 GAAP EPS $(1.47) Misses $(1.33) Estimate, Sales $17.054M Beat $16.522M Estimate
Portfolio Pulse from Benzinga Newsdesk
Enanta Pharma (NASDAQ:ENTA) reported Q2 2024 earnings with a GAAP EPS of $(1.47), missing the $(1.33) estimate by 10.53%, and sales of $17.054M, beating the $16.522M estimate by 3.22%. This represents a 17.88% improvement in EPS and a 4.16% decrease in sales from the same period last year.
May 06, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Enanta Pharma reported a Q2 2024 GAAP EPS of $(1.47), missing estimates, but sales of $17.054M exceeded expectations.
The mixed results with a miss on EPS but a beat on sales could lead to neutral market reaction in the short term. The improvement in EPS year-over-year indicates progress, but the decrease in sales might raise concerns.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100